Mengyuan Ge

University of Miami — United States

Medicine · Health Sciences

15h-index1.1kcitations36works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(15), Cholesterol and Lipid Metabolism(6), Diabetes Treatment and Management(5), Cell Adhesion Molecules Research(5), Cancer-related molecular mechanisms research(4)

Publications36 total

Corrigendum to “Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome” eBioMedicine, Volume 63, January 2021, 103162
EBioMedicine·2025Open Access
B-185 Why chromatography still matters: the case of an interference in two benzodiazepines LC-MS/MS methods from hospital and reference laboratories
Clinical Chemistry·2025Open Access
A Rapid Approach for Assessing Body Fluid Matrix Effects
The Journal of Applied Laboratory Medicine·2025Open Access
Measurement of Whole Blood Tacrolimus Concentrations by LC-MS/MS and Immunoassay Methods: Influence of Immediate-Release vs Extended-Release Tacrolimus Formulations
The Journal of Applied Laboratory Medicine·2025· 2 cited
Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens
The Journal of Applied Laboratory Medicine·2024· 3 citedOpen Access
Oxysterol-binding protein-like 7 deficiency leads to ER stress-mediated apoptosis in podocytes and proteinuria
American Journal of Physiology-Renal Physiology·2024· 4 citedOpen Access
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
Kidney360·2024· 3 citedOpen Access
ABCA1 deficiency contributes to podocyte pyroptosis priming via the APE1/IRF1 axis in diabetic kidney disease
Scientific Reports·2023· 16 citedOpen Access
Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
eLife·2023· 54 citedOpen Access
Author response: Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome
2023Open Access
Empagliflozin Reduces Renal Lipotoxicity in Alport Syndrome
Journal of the American Society of Nephrology·2022
Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases
Journal of the American Society of Nephrology·2022· 71 citedOpen Access
Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome
2022Open Access
LPCing through the nephron accelerates diabetic kidney disease
Kidney International·2022· 1 cited
Table of Contents
Kidney International·2022Open Access
Sphingomyelin phosphodiesterase acid like 3B (SMPDL3b) regulates Perilipin5 (PLIN5) expression and mediates lipid droplet formation
Genes & Diseases·2022· 5 citedOpen Access
POS-209 OXYSTEROL-BINDING PROTEIN LIKE 7 IN CHRONIC KIDNEY DISEASE
Kidney International Reports·2022Open Access
[Retracted] Systematic Review and Meta‐Analysis Program Based on Effectiveness of a Multidisciplinary Model of Care for Patients with Chronic Kidney Disease
Contrast Media & Molecular Imaging·2022· 3 citedOpen Access
Oxysterol-Binding Protein Like 7 in CKD
Journal of the American Society of Nephrology·2021
Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases
Journal of Personalized Medicine·2021· 11 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sandra Merscher(24), Alessia Fornoni(21), Alla Mitrofanova(16), Jin‐Ju Kim(16), Javier Varona Santos(15), Shamroop Kumar Mallela(14), Judith Molina(12), Gloria Michelle Ducasa(11), Alexis Sloan(11), Flavia Fontanesi(9), Armando J. Mendez(8), Hassan Al‐Ali(7), Jeffrey D. Pressly(6), Anis Ahmad(6), Christopher E. Pedigo(5), George W. Burke(5), Alessia Fornoni(5), Matthias Kretzler(4), Xiaochen Liu(4), Judith Molina David(4)